Novartis registers two Phase I trials: TRB191 in SCLC and XEP527 in schizophreniaNov 6Weekly roundup, 10 itemsArdtartemether and lumefantrine
Novartis roundup: ITP real-world data completed; three trials registered; Utah study terminatedSep 4Weekly roundup, 6 itemsDDY391inclisiran